Concepedia

Safety Profile Characterization

Safety Profile Characterization is a systematic pharmacovigilance framework that distinguishes itself by defining the qualitative and quantitative features of a drug’s adverse effect patterns relative to its therapeutic context, thereby enabling structured evaluation of its risk-benefit balance.

3.6K

Publications

207.8K

Citations

31.3K

Authors

6.3K

Institutions

Publications per year

2017–2026

1.9K

Parents

Publications

3.6K

Lenalidomide plus Dexamethasone for Relapsed Multiple Myeloma in North America

Donna M. Weber, Christine Chen, Rubén Niesvizky et al. · New England Journal of Medicine · 2007 · 1.2K citations · Full text

, , +14

Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma

Jeffrey S. Weber, F. Stephen Hodi, Jedd D. Wolchok et al. · Journal of Clinical Oncology · 2017 · 1.2K citations

, , +17

Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics

Claudio G. Brunstein, Jeffrey S. Miller, Qing Cao et al. · Blood · 2010 · 1K citations · Full text

, , +17

The safety profile of infliximab in patients with Crohn’s disease: The Mayo Clinic experience in 500 patients

Jean‐Frédéric Colombel, Edward V. Loftus, William J. Tremaine et al. · Gastroenterology · 2003 · 908 citations · Full text

, , +13

Phase III Study of Bevacizumab Plus Docetaxel Compared With Placebo Plus Docetaxel for the First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer

David Miles, Arlene Chan, Luc Dirix et al. · Journal of Clinical Oncology · 2010 · 887 citations

, , +17

1–5 of 3.6K

Authors

31.3K

  1. JT
    Josep Tabernero

    Vall d'Hebron Hospital Universitari, Spain

    17 publications · 1.8K citations

    16

    h-index

  2. EF
    Enriqueta Felip

    Vall d'Hebron Hospital Universitari, Spain

    20 publications · 1.4K citations

    16

    h-index

  3. EV
    Eric Van Cutsem

    KU Leuven, Belgium

    16 publications · 1.7K citations

    15

    h-index

  4. JC
    Johanna C. Bendell

    Sarah Cannon, United States

    15 publications · 1.1K citations

    14

    h-index

  5. MC
    Mark C. Genovese

    Stanford University, United States

    15 publications · 1.8K citations

    14

    h-index

1–5 of 31.3K

Institutions

6.3K

  1. The University of Texas MD Anderson Cancer Center

    Houston, United States

    55 h-index

    307 publications

    26.3K citations

  2. Memorial Sloan Kettering Cancer Center

    New York, United States

    51 h-index

    325 publications

    39K citations

  3. Inserm

    Paris, France

    50 h-index

    264 publications

    18K citations

  4. Dana-Farber Cancer Institute

    Boston, United States

    49 h-index

    204 publications

    17.7K citations

  5. Novartis (Switzerland)

    Basel, Switzerland

    44 h-index

    209 publications

    12.6K citations

  6. Eli Lilly (United States)

    Indianapolis, United States

    42 h-index

    324 publications

    23.2K citations

  7. Pfizer (United States)

    New York, United States

    42 h-index

    386 publications

    25.8K citations

  8. Bristol-Myers Squibb (United States)

    New York, United States

    42 h-index

    399 publications

    27.2K citations

1–8 of 6.3K

Venues

  1. Journal of Clinical Oncology

    364 publications · 27.8K citations

    74

    h-index

  2. Clinical Cancer Research

    61 publications · 6.1K citations

    42

    h-index

  3. PubMed

    Repository · 136 publications · 5.1K citations

    38

    h-index

  4. Cancer

    35 publications · 3.3K citations

    27

    h-index

  5. Annals of the Rheumatic Diseases

    ARD · 45 publications · 4.8K citations

    27

    h-index

1–5